CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer
-
Published:2024-04-01
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Cheng Maosheng, Chen Shuang, Li Kang, Wang Ganping, Xiong Gan, Ling RongsongORCID, Zhang Caihua, Zhang Zhihui, Han HuiORCID, Chen Zhi, Wang Xiaochen, Liang Yu, Tian Guoli, Zhou Ruoxing, Zhu Yan, Ma Jieyi, Liu Jiahong, Lin ShuibinORCID, Xu HaoORCID, Chen DemengORCID, Li YangORCID, Peng Liang
Abstract
AbstractInterplay between innate and adaptive immune cells is important for the antitumor immune response. However, the tumor microenvironment may turn immune suppressive, and tumor associated macrophages are playing a role in this transition. Here, we show that CD276, expressed on tumor-associated macrophages (TAM), play a role in diminishing the immune response against tumors. Using a model of tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in BLCA male mice we show that genetic ablation of CD276 in TAMs blocks efferocytosis and enhances the expression of the major histocompatibility complex class II (MHCII) of TAMs. This in turn increases CD4 + and cytotoxic CD8 + T cell infiltration of the tumor. Combined single cell RNA sequencing and functional experiments reveal that CD276 activates the lysosomal signaling pathway and the transcription factor JUN to regulate the expression of AXL and MerTK, resulting in enhanced efferocytosis in TAMs. Proving the principle, we show that simultaneous blockade of CD276 and PD-1 restrain tumor growth better than any of the components as a single intervention. Taken together, our study supports a role for CD276 in efferocytosis by TAMs, which is potentially targetable for combination immune therapy.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020). 2. von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608 (2005). 3. Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: Cancer J. Clin. 70, 404–423 (2020). 4. Liu, S. et al. The role of CD276 in cancers. Front. Oncol. 11, 654684 (2021). 5. Feng, R., Chen, Y., Liu, Y., Zhou, Q. & Zhang, W. The role of B7-H3 in tumors and its potential in clinical application. Int. Immunopharmacol. 101, 108153 (2021).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|